VIP (vasoactive intestinal peptide, aviptadil)
VIP is a signaling peptide the body makes in the gut, lungs and nerves. Its synthetic form is called aviptadil. Clinics prescribe it as a compounded nasal spray, mostly in protocols for mold-related illness. The best trials tested a different thing, an intravenous drip for severe COVID-19, and they did not show a benefit.
- Legal lane: not FDA-approved. Pharmacies may compound it on prescription while the FDA reviews it.
- Evidence grade: C for the nasal spray. One small series without a comparison group.
- Form: compounded nasal spray
- Also called: aviptadil, RLF-100, Zyesami
What it is
Vasoactive intestinal peptide is a chain of 28 amino acids. It was first isolated from the intestine and is found throughout the nervous system, lungs, gut and immune tissue. It relaxes blood vessels and airways and dampens some immune signals. It lasts only a very short time in the body, so how it is delivered matters a great deal.
What the evidence shows
- Intravenous, severe COVID-19: in a company-run trial of 196 patients, the main result did not reach statistical significance. In a larger government-backed trial, deaths at 90 days were 38% with aviptadil and 36% with placebo, and the trial was stopped early because it could not succeed.
- Nasal spray: the main published support is a report on 20 patients with a diagnosis of chronic inflammatory response syndrome who used the spray and were followed over time. There was no placebo group.
The diagnosis the spray is mostly prescribed for is itself contested. A medical training organization that reviewed VIP describes it as a peptide with real biology and a poor trial record, used without controlled evidence.
Legal status
- Not FDA-approved for any use. The FDA declined an emergency authorization request during the pandemic.
- It sits in Category 1 of the FDA's list of substances nominated for compounding, which means it is under evaluation and pharmacies may compound it on prescription in the meantime.
- That status can change when the FDA finishes its review.
Reported dosing
No dose has been established in a controlled trial.
The 20-patient series used 50 micrograms as a nasal spray four times a day. That is what one uncontrolled report did, under a physician. It is not a tested dose.
Safety
- VIP widens blood vessels and increases secretion in the gut, so low blood pressure and diarrhea are the expected side effects, along with nasal irritation from a spray.
- Long-term safety of the nasal spray has not been studied in a controlled trial.
- A compounded spray has no FDA label. Quality depends on the pharmacy.
Common questions
Is VIP FDA-approved?
No. It can be compounded on prescription while the FDA evaluates it.
Did aviptadil work for COVID-19?
No. The large trial was stopped early, with 90-day deaths of 38% on aviptadil and 36% on placebo.
What is VIP nasal spray used for?
Mostly protocols for chronic inflammatory response syndrome, a contested diagnosis linked to water-damaged buildings. The support is one small uncontrolled series.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.
Sources
- Randomized trial of intravenous aviptadil in critical COVID-19 (PMC)
- Superpower: the futility result and approval status
- FDA: bulk drug substances nominated for compounding under section 503A, by category
- Peptide Benchmark: Category 1 status and the 20-patient nasal spray series
- Empire Medical Training: trial record, half-life and off-label use
- BioSpace: the 196-patient trial and the declined emergency authorization